Anticonvulsant Explained

Synonyms:Antiepileptic drugs, antiseizure drugs
Use:Epilepsy
Atc Prefix:N03
Biological Target:Brain

Anticonvulsants (also known as antiepileptic drugs, antiseizure drugs, or anti-seizure medications (ASM)) are a diverse group of pharmacological agents used in the treatment of epileptic seizures.[1] Anticonvulsants are also increasingly being used in the treatment of bipolar disorder[2] [3] and borderline personality disorder,[4] since many seem to act as mood stabilizers, and for the treatment of neuropathic pain.[5] Anticonvulsants suppress the excessive rapid firing of neurons during seizures.[6] Anticonvulsants also prevent the spread of the seizure within the brain.[7]

Conventional antiepileptic drugs may block sodium channels or enhance γ-aminobutyric acid (GABA) function. Several antiepileptic drugs have multiple or uncertain mechanisms of action.[8] Next to the voltage-gated sodium channels and components of the GABA system, their targets include GABAA receptors, the GABA transporter type 1, and GABA transaminase.[9] Additional targets include voltage-gated calcium channels, SV2A, and α2δ.[10] [11] By blocking sodium or calcium channels, antiepileptic drugs reduce the release of excitatory glutamate, whose release is considered to be elevated in epilepsy, but also that of GABA.[12] This is probably a side effect or even the actual mechanism of action for some antiepileptic drugs, since GABA can itself, directly or indirectly, act proconvulsively. Another potential target of antiepileptic drugs is the peroxisome proliferator-activated receptor alpha.[13] [14] [15] [16] [17] [18] [19]

Some anticonvulsants have shown antiepileptogenic effects in animal models of epilepsy.[20] That is, they either prevent the development of epilepsy or can halt or reverse the progression of epilepsy. However, no drug has been shown in human trials to prevent epileptogenesis (the development of epilepsy in an individual at risk, such as after a head injury).[21]

Terminology

Anticonvulsants are more accurately called antiepileptic drugs (AEDs) because not every epileptic seizure involves convulsion, and vice versa, not every convulsion is caused by an epileptic seizure.[22] They are also often referred to as antiseizure drugs because they provide symptomatic treatment only and have not been demonstrated to alter the course of epilepsy.[23]

Approval

The usual method of achieving approval for a drug is to show it is effective when compared against placebo, or that it is more effective than an existing drug. In monotherapy (where only one drug is taken) it is considered unethical by most to conduct a trial with placebo on a new drug of uncertain efficacy. This is because untreated epilepsy leaves the patient at significant risk of death. Therefore, almost all new epilepsy drugs are initially approved only as adjunctive (add-on) therapies. Patients whose epilepsy is uncontrolled by their medication (i.e., it is refractory to treatment) are selected to see if supplementing the medication with the new drug leads to an improvement in seizure control. Any reduction in the frequency of seizures is compared against a placebo.[21] The lack of superiority over existing treatment, combined with lacking placebo-controlled trials, means that few modern drugs have earned FDA approval as initial monotherapy. In contrast, Europe only requires equivalence to existing treatments and has approved many more. Despite their lack of FDA approval, the American Academy of Neurology and the American Epilepsy Society still recommend a number of these new drugs as initial monotherapy.[21]

Drugs

In the following list, the dates in parentheses are the earliest approved use of the drug.

Aldehydes

See main article: Aldehyde.

Aromatic allylic alcohols

Barbiturates

See main article: Barbiturate. Barbiturates are drugs that act as central nervous system (CNS) depressants, and by virtue of this they produce a wide spectrum of effects, from mild sedation to anesthesia. The following are classified as anticonvulsants:[29]

Benzodiazepines

See main article: Benzodiazepine. The benzodiazepines are a class of drugs with hypnotic, anxiolytic, anticonvulsive, amnestic and muscle relaxant properties. Benzodiazepines act as a central nervous system depressant. The relative strength of each of these properties in any given benzodiazepine varies greatly and influences the indications for which it is prescribed. Long-term use can be problematic due to the development of tolerance to the anticonvulsant effects and dependency.[30] [31] [32] [33] Of many drugs in this class, only a few are used to treat epilepsy:

The following benzodiazepines are used to treat status epilepticus:

Nitrazepam, temazepam, and especially nimetazepam are powerful anticonvulsant agents, however their use is rare due to an increased incidence of side effects and strong sedative and motor-impairing properties.

Bromides

See main article: Bromide.

Carbamates

See main article: Carbamate.

Carboxamides

See main article: Carboxamide. The following are carboxamides:

Fatty acids

See main article: Fatty acid. The following are fatty-acids:

Vigabatrin and progabide are also analogs of GABA.

Fructose derivatives

See main article: Fructose.

Gabapentinoids

See main article: Gabapentinoid.

Gabapentinoids are used in epilepsy, neuropathic pain, fibromyalgia, restless leg syndrome, opioid withdrawal and generalized anxiety disorder (GAD). Gabapentinoids block voltage-gated calcium channels, mainly the N-Type, and P/Q-type calcium channels. The following are gabapentinoids:

Gabapentinoids are analogs of GABA, but they do not act on GABA receptors. They have analgesic, anticonvulsant, and anxiolytic effects.

Hydantoins

See main article: Hydantoin. The following are hydantoins:

Oxazolidinediones

See main article: 2,4-Oxazolidinedione. The following are oxazolidinediones:

Propionates

See main article: Propionate.

Pyrimidinediones

See main article: Pyrimidinedione.

Pyrrolidines

See main article: Pyrrolidine.

Succinimides

See main article: Succinimide. The following are succinimides:

Sulfonamides

See main article: Sulfonamide (medicine).

Triazines

See main article: Triazine.

Ureas

See main article: Urea.

Valproylamides

See main article: Amide.

Other

Non-pharmaceutical anticonvulsants

The ketogenic diet and vagus nerve stimulation are alternative treatments for epilepsy without the involvement of pharmaceuticals. The ketogenic diet consists of a high-fat, low-carbohydrate diet, and has shown good results in patients whose epilepsy has not responded to medications and who cannot receive surgery. The vagus nerve stimulator is a device that can be implanted into patients with epilepsy, especially that which originates from a specific part of the brain. However, both of these treatment options can cause severe adverse effects. Additionally, while seizure frequency typically decreases, they often do not stop entirely.[39] [40]

Treatment guidelines

According to guidelines by the American Academy of Neurology and American Epilepsy Society,[41] mainly based on a major article review in 2004,[42] patients with newly diagnosed epilepsy who require treatment can be initiated on standard anticonvulsants such as carbamazepine, phenytoin, valproic acid/valproate semisodium, phenobarbital, or on the newer anticonvulsants gabapentin, lamotrigine, oxcarbazepine or topiramate. The choice of anticonvulsants depends on individual patient characteristics.[41] Both newer and older drugs are generally equally effective in new onset epilepsy.[41] The newer drugs tend to have fewer side effects.[41] For newly diagnosed partial or mixed seizures, there is evidence for using gabapentin, lamotrigine, oxcarbazepine or topiramate as monotherapy.[41] Lamotrigine can be included in the options for children with newly diagnosed absence seizures.[41]

History

The first anticonvulsant was bromide, suggested in 1857 by the British gynecologist Charles Locock who used it to treat women with "hysterical epilepsy" (probably catamenial epilepsy). Bromides are effective against epilepsy, and also cause impotence, which is not related to its anti-epileptic effects. Bromide also suffered from the way it affected behaviour, introducing the idea of the "epileptic personality" which was actually a result of medication. Phenobarbital was first used in 1912 for both its sedative and antiepileptic properties. By the 1930s, the development of animal models in epilepsy research led to the development of phenytoin by Tracy Putnam and H. Houston Merritt, which had the distinct advantage of treating epileptic seizures with less sedation.[43] By the 1970s, a National Institutes of Health initiative, the Anticonvulsant Screening Program, headed by J. Kiffin Penry, served as a mechanism for drawing the interest and abilities of pharmaceutical companies in the development of new anticonvulsant medications.

Marketing approval history

The following table lists anticonvulsant drugs together with the date their marketing was approved in the US, UK and France. Data for the UK and France are incomplete. The European Medicines Agency approves drugs throughout the European Union. Some of the drugs are no longer marketed.

DrugBrandUSUKFrance
acetazolamideDiamox1953-07-2727 July 1953[44] 1988[45]
brivaracetamBriviact2016-02-1818 February 2016[46] [47]
carbamazepineTegretol1974-07-1515 July 1974[48] [49] 19651963[50]
cenobamateXcopri2019-11-2121 November 2019
clobazamOnfi/Frisium2011-10-2121 October 2011[51] [52] 1979
clonazepamKlonopin/Rivotril1975-06-044 June 1975[53] 1974
diazepamValium1963-11-1515 November 1963[54]
divalproex sodiumDepakote1983-03-1010 March 1983[55]
eslicarbazepineAptiom2013-08-1111 August 2013[56] [57]
ethosuximideZarontin1960-11-022 November 1960[58] 19551962
ethotoinPeganone1957-04-2222 April 1957[59]
everolimusAfinitor/Votubia2009-03-3030 January 2009[60]
felbamateFelbatol1993-07-2929 July 1993[61]
fosphenytoinCerebyx1996-08-055 August 1996[62]
gabapentinNeurontin1993-12-3030 December 1993[63] 1993-05May 19931994-10October 1994
lacosamideVimpat2008-10-2828 October 2008[64]
lamotrigineLamictal1994-12-2727 December 1994[65] 1991-10October 19911995-05May 1995
levetiracetamKeppra1999-11-3030 November 1999[66] 2000-09-2929 September 2000[67] 2000-09-2929 September 2000
mephenytoinMesantoin1946-10-2323 October 1946[68]
metharbitalGemonil1952[69] [70]
methsuximideCelontin1957-02-088 February 1957[71]
methazolamideNeptazane1959-01-2626 January 1959[72]
oxcarbazepineTrileptal2000-01-1414 January 2000[73] 2000
phenobarbitalLuminal Unknown19121920
phenytoinDilantin/Epanutin1938[74] 19381941
piracetamNootropilnever approved
phensuximideMilontin1953[75] [76]
pregabalinLyrica2004-12-3030 December 2004[77] 2004-07-066 July 2004[78] 2004-07-066 July 2004
primidoneMysoline1954-03-088 March 1954[79] 19521953
rufinamideBanzel/Inovelon2008-11-1414 November 2008[80] [81]
sodium valproateEpilimUnknown1977-12December 19771967-06June 1967
stiripentolDiacomit2018-08-2020 August 2018[82] [83] 2007-01January 20072007-01January 2007
tiagabineGabitril1997-09-3030 September 1997[84] [85] 19981997-11November 1997
topiramateTopamax1996-12-2424 December 1996[86] 1995
trimethadioneTridione1946-01-2525 January 1946[87]
valproic acidDepakene/Convulex1978-02-2828 February 1978[88] 1993
vigabatrinSabril2009-08-2121 August 2009[89] 1989
zonisamideZonegran2000-03-2727 March 2000[90] 2005-03-1010 March 2005[91] 2005-03-1010 March 2005

Pregnancy

See also: Epilepsy and pregnancy.

Many of the commonly used anticonvulsant/anti-seizure medications (ASMs), such as valproate, phenytoin, carbamazepine, phenobarbitol, gabapentin have been reported to cause an increased risk of birth defects including major congenital malformations such as neural tube defects.[92] The risk of birth defects associated with taking these medications while pregnant may be dependent on the dose and on the timing of gestation (how well developed the baby is). While trying to conceive a child and during pregnancy, medical advice should be followed to optimize the management of the person's epilepsy in order to keep the person and the unborn baby safe from epileptic seizures and also ensure that the risk of birth defects due to in utero exposure of anticonvulsants is as low as possible. Use of anticonvulsant medications should be carefully monitored during use in pregnancy.[93] For example, since the first trimester is the most susceptible period for fetal development, planning a routine antiepileptic drug dose that is safer for the first trimester could be beneficial to prevent pregnancy complications.[94]

Valproic acid, and its derivatives such as sodium valproate and divalproex sodium, causes cognitive deficit in the child, with an increased dose causing decreased intelligence quotient and use is associated with adverse neurodevelopmental outcomes (cognitive and behavioral)  in children.[95] [96] On the other hand, evidence is conflicting for carbamazepine regarding any increased risk of congenital physical anomalies or neurodevelopmental disorders by intrauterine exposure. Similarly, children exposed lamotrigine or phenytoin in the womb do not seem to differ in their skills compared to those who were exposed to carbamazepine.

There is inadequate evidence to determine if newborns of women with epilepsy taking anticonvulsants have a substantially increased risk of hemorrhagic disease of the newborn.[93]

There is little evidence to suggest that anticonvulsant/ASM exposure through breastmilk has clinical effects on newborns. The Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs (MONEAD) study showed that most blood concentrations in breastfed infants of mothers taking carbamazepine, oxcarbazepine, valproate, levetiracetam, and topiramate were quite low, especially in relationship to the mother's level and what the fetal level would have been during pregnancy. (Note: valproic acid is NOT a recommended ASM for people with epilepsy who are considering having children.) [97]

Infant exposure to newer ASMs (cenobamate, perampanel, brivaracetam, eslicarbazepine, rufinamide, levetiracetam, topiramate, gabapentin, oxcarbazepine, lamotrigine, and vigabatrin) via breastmilk was not associated with negative neurodevelopment (such as lower IQ and autism spectrum disorder) at 36 months.[98]

Several studies that followed children exposed to ASMs during pregnancy showed that a number of widely used ones (including lamotrigine and levetiracetam) carried a low risk of adverse neurodevelopmental outcomes (cognitive and behavioral) in children when compared to children born to mothers without epilepsy and children born to mothers taking other anti-seizure medications. Data from several pregnancy registries showed that children exposed to levetiracetam or lamotrigine during pregnancy had the lowest risk of developing major congenital malformations compared to those exposed to other ASMs. The risk of major congenital malformations for children exposed to these ASMs were within the range for children who were not exposed to any ASMs during pregnancy.[99]

People with epilepsy can have healthy pregnancies and healthy babies. However, proper planning and care is essential to minimize the risk of congenital malformations or adverse neurocognitive outcomes for the fetus while maintaining seizure control for the pregnant person with epilepsy. If possible, when planning pregnancy, people with epilepsy should switch to ASMs with the lowest teratogenic risk for major congenital malformations as well as the least risk of adverse neurodevelopmental outcomes (e.g., lower IQ or autism spectrum disorder). They should also work with their healthcare providers to identify the lowest effective ASM dosage that will maintain their seizure control while regularly checking medication levels throughout pregnancy.[100]

Data from studies conducted on women taking antiepileptic drugs for non-epileptic reasons, including depression and bipolar disorder, show that if high doses of the drugs are taken during the first trimester of pregnancy then there is the potential of an increased risk of congenital malformations.[101]

Research

The mechanism of how anticonvulsants cause birth defects is not entirely clear. During pregnancy, the metabolism of many anticonvulsants is affected. There may be an increase in the clearance and resultant decrease in the blood concentration of lamotrigine, phenytoin, and to a lesser extent carbamazepine, and possibly decreases the level of levetiracetam and the active oxcarbazepine metabolite, the monohydroxy derivative. In animal models, several anticonvulsant drugs have been demonstrated to induce neuronal apoptosis in the developing brain.[102] [103] [104] [105] [106]

Further reading

External links

Notes and References

  1. Al-Otaibi . Faisal . An overview of structurally diversified anticonvulsant agents . Acta Pharmaceutica (Zagreb, Croatia) . Walter de Gruyter GmbH . 69 . 3 . 2019-09-01 . 1846-9558 . 31259739 . 10.2478/acph-2019-0023 . 321–344. free .
  2. Joshi . A . Bow . A . Agius . M . Pharmacological Therapies in Bipolar Disorder: a Review of Current Treatment Options. . Psychiatria Danubina . 31 . Suppl 3 . 2019 . 0353-5053 . 31488797 . 595–603.
  3. Keck. Paul E. Jr.. McElroy. Susan L.. Susan McElroy. Strakowski. Stephen M.. Anticonvulsants and antipsychotics in the treatment of bipolar disorder.. The Journal of Clinical Psychiatry. 1998. 59. Suppl 6. 74–82. 9674940.
  4. American Psychiatric Association, and American Psychiatric Association. Work Group on Borderline Personality Disorder. Practice guideline for the treatment of patients with borderline personality disorder. American Psychiatric Pub, 2001.
  5. Rogawski. Michael A.. Löscher. Wolfgang. The neurobiology of antiepileptic drugs. Nature Reviews Neuroscience. 2004. 5. 7. 553–564. 10.1038/nrn1430. 15208697. 2201038. 20 September 2020. 16 December 2020. https://web.archive.org/web/20201216114030/https://zenodo.org/record/1233562. live.
  6. McLean. M J. Macdonald. R L. Sodium valproate, but not ethosuximide, produces use- and voltage-dependent limitation of high frequency repetitive firing of action potentials of mouse central neurons in cell culture.. Journal of Pharmacology and Experimental Therapeutics. June 1986. 237. 3. 1001–1011. 3086538.
  7. Harden. C. L.. New antiepileptic drugs. Neurology. 1 May 1994. 44. 5. 787–95. 10.1212/WNL.44.5.787. 8190276. 75925846.
  8. Web site: Archived copy . 2013-01-28 . https://web.archive.org/web/20131103055041/https://www.neurology.wisc.edu/publications/2010%20pubs/stafstrom-4.pdf . 3 November 2013.
  9. 15208697 . 10.1038/nrn1430 . 5 . 7 . The neurobiology of antiepileptic drugs . July 2004 . Rogawski MA, Löscher W . Nature Reviews Neuroscience . 553–64 . 2201038 . 20 September 2020 . 16 December 2020 . https://web.archive.org/web/20201216114030/https://zenodo.org/record/1233562 . live .
  10. 18590620 . 8 . 4 . New molecular targets for antiepileptic drugs: alpha(2)delta, SV2A, and K(v)7/KCNQ/M potassium channels . 2587091 . July 2008 . Rogawski MA, Bazil CW . Curr Neurol Neurosci Rep . 345–52 . 10.1007/s11910-008-0053-7 .
  11. 17199015 . 10.1016/j.nurt.2006.11.010 . 4 . 1 . Molecular targets for antiepileptic drug development . 1852436 . January 2007 . Meldrum BS, Rogawski MA . Neurotherapeutics . 18–61 .
  12. Kammerer. M.. Rassner, M. P.. Freiman, T. M.. Feuerstein, T. J.. Effects of antiepileptic drugs on GABA release from rat and human neocortical synaptosomes. Naunyn-Schmiedeberg's Archives of Pharmacology. 2 May 2011. 384. 1. 47–57. 10.1007/s00210-011-0636-8. 21533993. 1388805.
  13. Puligheddu M, Pillolla G, Melis M, Lecca S, Marrosu F, De Montis MG . PPAR-alpha agonists as novel antiepileptic drugs: preclinical findings . PLOS ONE . 2013 . 8 . 5 . e64541 . 23724059 . 10.1371/journal.pone.0064541 . 3664607 . 2013PLoSO...864541P . Charpier. Stéphane . etal . free .
  14. Citraro R, Russo E, Scicchitano F, van Rijn CM, Cosco D, Avagliano C, Russo R, D'Agostino G, Petrosino S, Guida F, Gatta L, van Luijtelaar G, Maione S, Di Marzo V, Calignano A, De Sarro G . Antiepileptic action of N-palmitoylethanolamine through CB1 and PPAR-α receptor activation in a genetic model of absence epilepsy . Neuropharmacology . 2013 . 69 . 115–26 . 10.1016/j.neuropharm.2012.11.017 . 23206503 . 27701532 . 1.
  15. Porta, N. . Vallée, L. . Lecointe, C. . Bouchaert, E. . Staels, B. . Bordet, R. . Auvin, S. . 2009 . Fenofibrate, a peroxisome proliferator-activated receptor-alpha agonist, exerts anticonvulsive properties. . Epilepsia . 50 . 4 . 943–8 . 19054409 . 10.1111/j.1528-1167.2008.01901.x. 6796135 . free .
  16. Lampen A, Carlberg C, Nau H. Peroxisome proliferator-activated receptor delta is a specific sensor for teratogenic valproic acid derivatives . Eur J Pharmacol . 2001 . 431 . 1 . 25–33 . 10.1016/S0014-2999(01)01423-6. 11716839 .
  17. Maguire JH, Murthy AR, Hall IH. Hypolipidemic activity of antiepileptic 5-phenylhydantoins in mice . Eur J Pharmacol . 1985 . 117 . 1 . 135–8 . 10.1016/0014-2999(85)90483-2. 4085542 .
  18. Hall IH, Patrick MA, Maguire JH. Hypolipidemic activity in rodents of phenobarbital and related derivatives . Archiv der Pharmazie . 1990 . 323 . 9 . 579–86 . 10.1002/ardp.19903230905. 2288480 . 46002731 .
  19. Frigerio F, Chaffard G, Berwaer M, Maechler P. The antiepileptic drug topiramate preserves metabolism-secretion coupling in insulin secreting cells chronically exposed to the fatty acid oleate . Biochem Pharmacol . 2006 . 72 . 8 . 965–73 . 10.1016/j.bcp.2006.07.013 . 16934763 .
  20. 24671870. 2014. Kaminski. R. M.. The potential of antiseizure drugs and agents that act on novel molecular targets as antiepileptogenic treatments. Neurotherapeutics. 11. 2. 385–400. Rogawski. M. A.. Klitgaard. H. 10.1007/s13311-014-0266-1. 3996125.
  21. Abou-Khalil BW . Comparative Monotherapy Trials and the Clinical Treatment of Epilepsy . Epilepsy Currents . 7 . 5 . 127–9 . 2007 . 17998971 . 10.1111/j.1535-7511.2007.00198.x . 2043140.
  22. Web site: Antiseizure medication . 2024-03-16 . Cleveland Clinic . en . 16 March 2024 . https://web.archive.org/web/20240316202242/https://my.clevelandclinic.org/health/treatments/24781-antiseizure-medications-anticonvulsants . live .
  23. Book: Rogawski . Michael. 2021 . Katzung . B . Basic and Clinical Pharmacology, 15th Edition . McGraw-Hill Education. 422–455 . Chapter 24: Antiseizure Drugs.
  24. Browne TR. Paraldehyde, chlormethiazole, and lidocaine for treatment of status epilepticus. In: Delgado-Escueta AV, Wasterlain CG, Treiman DM, Porter RJ, eds. Status Epilepticus. Mechanisms of Brain Damage and Treatment (Advances in Neurology, Vol 34). New York, Raven Press 1983: 509–517
  25. Ramsay RE . 1989 . Pharmacokinetics and clinical use of parenteral phenytoin, phenobarbital, and paraldehyde . Epilepsia . 30 . Suppl 2. S1–S3 . 10.1111/j.1528-1157.1989.tb05818.x . 2767008 . 44798815 .
  26. Plosker. GL. Stiripentol: in severe myoclonic epilepsy of infancy (dravet syndrome). CNS Drugs. November 2012. 26. 11. 993–1001. 23018548. 10.1007/s40263-012-0004-3. 42911844 .
  27. Web site: Public summary of positive opinion for orpphan opinion for orphan designation of stiripentol for the treatment of severe myoclonic epilepsy in infancy. European Medicines Agency. 19 May 2013. 30 July 2007. Doc.Ref.: EMEA/COMP/269/04. 17 December 2013. https://web.archive.org/web/20131217120247/http://www.ema.europa.eu/docs/en_GB/document_library/Orphan_designation/2009/10/WC500005711.pdf. dead.
  28. Web site: Diacomit- stiripentol capsule Diacomit- stiripentol powder, for suspension . DailyMed . 15 May 2020 . 8 November 2020 . 6 August 2020 . https://web.archive.org/web/20200806164938/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=58304ba8-9779-4658-811e-94ffe08c3f16#section-1 . live .
  29. Suddock JT, Kent KJ, Cain MD. Barbiturate Toxicity. 2023 Apr 12. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan–. PMID 29763050.(26 / August / 2023)
  30. Browne TR . May 1976 . Clonazepam. A review of a new anticonvulsant drug . 33 . 5 . 326–32 . 817697 . Arch Neurol . 10.1001/archneur.1976.00500050012003.
  31. Isojärvi . JI . Tokola RA . December 1998 . Benzodiazepines in the treatment of epilepsy in people with intellectual disability . J Intellect Disabil Res . 42 . 1 . 80–92 . 10030438.
  32. Epilepsia . May–Jun 1986 . 27 . 3 . 276–85 . Nonconvulsive status epilepticus. Svanborg . E . Wedlund . JE . 3698940 . Tomson . T . 10.1111/j.1528-1157.1986.tb03540.x. 26694857 .
  33. Djurić . M . Marjanović B . Zamurović D . May–Jun 2001 . [West syndrome--new therapeutic approach] . Srp Arh Celok Lek . 129 . 1 . 72–7 . 15637997.
  34. Book: Pediatric epilepsy: diagnosis and therapy . Demos Medical Publishing . 978-1-933864-16-7 . Bourgeois . Blaise F. . 3rd . New York . 2007-12-16 . Dodson . Edwin . Nordli . Douglas R. Jr . Pellock . John M. . Sankar . Raman.
  35. French. J. Smith, M. Faught, E. Brown, L. Practice advisory: The use of felbamate in the treatment of patients with intractable epilepsy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology. 12 May 1999. 52. 8. 1540–5. 10331676. 10.1212/WNL.52.8.1540. free.
  36. Web site: Felbamate. MedlinePlus : U.S. National Library of Medicine. 19 May 2013. 20 May 2013. https://web.archive.org/web/20130520184744/http://www.nlm.nih.gov/medlineplus/druginfo/meds/a606011.html. live.
  37. Camerin . Luisa . Maleeva . Galyna . Gomila-Juaneda . Alexandre . Suárez-Pereira . Irene . Matera . Carlo . Prischich . Davia . Opar . Ekin . Riefolo . Fabio . Berrocoso . Esther . Gorostiza . Pau . 2024-06-18 . Photoswitchable carbamazepine analogs for non-invasive neuroinhibition in vivo . Angewandte Chemie International Edition . en . 10.1002/anie.202403636 . 1433-7851. free .
  38. Web site: Diacomit EPAR . European Medicines Agency . 8 November 2020 . 12 November 2020 . https://web.archive.org/web/20201112022416/https://www.ema.europa.eu/en/medicines/human/EPAR/diacomit . live .
  39. D'Andrea Meira . Isabella . Ketogenic Diet and Epilepsy: What We Know So Far . 2019 . 13 . 5 . Frontiers in Neuroscience . 10.3389/fnins.2019.00005 . 30760973 . 6361831 . ketogenic . free .
  40. Web site: Pruthi . Sandhya . Vagus nerve stimulation . Mayo Clinic . 20 July 2023 . vagus . 20 July 2023 . https://web.archive.org/web/20230720033902/https://www.mayoclinic.org/tests-procedures/vagus-nerve-stimulation/about/pac-20384565 . live .
  41. http://aan.com/professionals/practice/pdfs/clinician_ep_onset_e.pdf AAN Guideline Summary for Clinicians – Efficacy and Tolerability of the New Antiepileptic Drugs, I: Treatment of New Onset Epilepsy
  42. French JA, Kanner AM, Bautista J . Efficacy and tolerability of the new antiepileptic drugs, I: Treatment of new-onset epilepsy: report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society . Epilepsia . 45 . 5 . 401–9 . May 2004 . 15101821 . 10.1111/j.0013-9580.2004.06204.x . etal . 2027.42/65231 . 12259676 . free . 30 August 2019 . 27 August 2021 . https://web.archive.org/web/20210827222145/https://deepblue.lib.umich.edu/bitstream/handle/2027.42/65231/j.0013-9580.2004.06204.x.pdf;jsessionid=89DC629D3B2965981B6AEA7B64498484?sequence=1 . live .
  43. Book: Eadie . M.J. . Bladin . P.F. . A Disease Once Sacred: A History of the Medical Understanding of Epilepsy . John Libbey . 2001 . 978-0-86196-607-3 . 2024-06-29 .
  44. Web site: New Drug Application (NDA) 008943 . U.S. Food and Drug Administration (FDA) . Drugs@FDA . 21 November 2019 . 19 October 2020 . https://web.archive.org/web/20201019225210/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=008943 . live .
  45. http://www.epilepsy.org.uk/info/drugslist.html Epilepsy Action: Druglist.
  46. Web site: New Drug Application (NDA) 205836 . U.S. Food and Drug Administration (FDA) . Drugs@FDA . 21 November 2019 . 19 October 2020 . https://web.archive.org/web/20201019081700/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205836 . live .
  47. Web site: Drug Approval Package: Briviact (brivaracetam) . U.S. Food and Drug Administration (FDA) . 30 March 2016 . https://web.archive.org/web/20191122035432/https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/205836-205837-205838-Briviact-TOC.cfm . 22 November 2019 . live . 21 November 2019.
  48. Web site: New Drug Application (NDA) 016608 . U.S. Food and Drug Administration (FDA) . Drugs@FDA . 21 November 2019 . 19 October 2020 . https://web.archive.org/web/20201019045718/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=016608 . live . (Initial approval on 11 March 1968 was for trigeminal neuralgia.)
  49. Schain . Richard J. . 1 March 1978. Pediatrics—Epitomes of Progress: Carbamazepine (Tegretol) in the Treatment of Epilepsy . Western Journal of Medicine . 128 . 3 . 231–232 . 18748164 . 1238063 .
  50. Loiseau . Pierre Jean-Marie . June 1999 . Clinical Experience with New Antiepileptic Drugs: Antiepileptic Drugs in Europe . . 40 . Suppl 6 . S3–8 . 10.1111/j.1528-1157.1999.tb00925.x . 10530675 . 29638422 . free .
  51. Web site: New Drug Application (NDA) 202067 . U.S. Food and Drug Administration (FDA) . Drugs@FDA . 21 November 2019 . 28 October 2020 . https://web.archive.org/web/20201028081126/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202067 . live .
  52. Web site: Drug Approval Package: Onfi NDA #202067 . U.S. Food and Drug Administration (FDA) . 20 August 2013 . https://web.archive.org/web/20191122035714/https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202067Orig1s000TOC.cfm . 22 November 2019 . live . 21 November 2019.
  53. Web site: New Drug Application (NDA) 017533 . U.S. Food and Drug Administration (FDA) . Drugs@FDA . 21 November 2019 . 20 October 2020 . https://web.archive.org/web/20201020082915/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017533 . live .
  54. Web site: New Drug Application (NDA) 013263 . U.S. Food and Drug Administration (FDA) . Drugs@FDA . 21 November 2019 . 19 October 2020 . https://web.archive.org/web/20201019195427/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=013263 . live .
  55. Web site: New Drug Application (NDA) 018723 . U.S. Food and Drug Administration (FDA) . Drugs@FDA . 21 November 2019 . 19 October 2020 . https://web.archive.org/web/20201019160555/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018723 . live .
  56. Web site: New Drug Application (NDA) 022416 . U.S. Food and Drug Administration (FDA) . Drugs@FDA . 21 November 2019 . 20 October 2020 . https://web.archive.org/web/20201020134600/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022416 . live .
  57. Web site: Drug Approval Package: Brand Name (Generic Name) NDA # . U.S. Food and Drug Administration (FDA) . 20 December 2013 . https://web.archive.org/web/20191122040059/https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/022416Orig1s000TOC.cfm . 22 November 2019 . live . 21 November 2019.
  58. Web site: New Drug Application (NDA) 012380 . U.S. Food and Drug Administration (FDA) . Drugs@FDA . 21 November 2019 . 30 November 2017 . https://web.archive.org/web/20171130231459/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=012380 . live .
  59. Web site: New Drug Application (NDA) 010841 . U.S. Food and Drug Administration (FDA) . Drugs@FDA . 21 November 2019 . 19 October 2020 . https://web.archive.org/web/20201019095022/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=010841 . live .
  60. Web site: New Drug Application (NDA) 022334 . U.S. Food and Drug Administration (FDA) . Drugs@FDA . 21 November 2019 . 31 October 2020 . https://web.archive.org/web/20201031140036/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022334 . live .
  61. Web site: New Drug Application (NDA) 020189 . U.S. Food and Drug Administration (FDA) . Drugs@FDA . 21 November 2019 . 21 October 2020 . https://web.archive.org/web/20201021172553/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020189 . live .
  62. Web site: New Drug Application (NDA) 020450 . U.S. Food and Drug Administration (FDA) . Drugs@FDA . 21 November 2019 . 20 October 2020 . https://web.archive.org/web/20201020182045/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020450 . live .
  63. Web site: New Drug Application (NDA) 020235 . U.S. Food and Drug Administration (FDA) . Drugs@FDA . 21 November 2019 . 19 October 2020 . https://web.archive.org/web/20201019005440/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020235 . live .
  64. Web site: New Drug Application (NDA) 022253 . U.S. Food and Drug Administration (FDA) . Drugs@FDA . 21 November 2019 . 20 October 2020 . https://web.archive.org/web/20201020110027/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022253 . live .
  65. Web site: New Drug Application (NDA) 020241 . U.S. Food and Drug Administration (FDA) . Drugs@FDA . 21 November 2019 . 24 October 2020 . https://web.archive.org/web/20201024035351/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020241 . live .
  66. Web site: New Drug Application (NDA) 021035 . U.S. Food and Drug Administration (FDA) . Drugs@FDA . 21 November 2019 . 21 October 2020 . https://web.archive.org/web/20201021171049/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021035 . live .
  67. http://www.emea.europa.eu/humandocs/Humans/EPAR/keppra/keppra.htm EPAR: Keppra.
  68. Web site: New Drug Application (NDA) 006008 . U.S. Food and Drug Administration (FDA) . Drugs@FDA . 21 November 2019 . 20 October 2020 . https://web.archive.org/web/20201020185537/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=006008 . live .
  69. Web site: New Drug Application (NDA) 008322 . U.S. Food and Drug Administration (FDA) . Drugs@FDA . 21 November 2019 . 19 October 2020 . https://web.archive.org/web/20201019003157/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=008322 . live .
  70. Book: Dodson, W. Edwin . Giuliano Avanzini . Shorvon, Simon D. . Fish, David R. . Emilio Perucca . The treatment of epilepsy . Blackwell Science . Oxford . 2004 . xxviii . 978-0-632-06046-7 . true.
  71. Web site: New Drug Application (NDA) 010596 . U.S. Food and Drug Administration (FDA) . Drugs@FDA . 21 November 2019 . 19 October 2020 . https://web.archive.org/web/20201019111530/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=010596 . live .
  72. Web site: New Drug Application (NDA) 011721 . U.S. Food and Drug Administration (FDA) . Drugs@FDA . 21 November 2019 . 19 October 2020 . https://web.archive.org/web/20201019013706/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=011721 . live .
  73. Web site: New Drug Application (NDA) 021014 . U.S. Food and Drug Administration (FDA) . Drugs@FDA . 21 November 2019 . 19 October 2020 . https://web.archive.org/web/20201019225416/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021014 . live .
  74. Web site: New Drug Application (NDA) 008762 . U.S. Food and Drug Administration (FDA) . Drugs@FDA . 21 November 2019 . 16 December 2020 . https://web.archive.org/web/20201216113543/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=008762 . live . (Marketed in 1938, approved 1953)
  75. Web site: New Drug Application (NDA) 008855 . U.S. Food and Drug Administration (FDA) . Drugs@FDA . 21 November 2019 . 26 July 2020 . https://web.archive.org/web/20200726070022/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=008855 . live .
  76. Book: Kutt, Henn . Resor, Stanley R. . The Medical treatment of epilepsy . Dekker . New York . 1992 . 385 . 978-0-8247-8549-9. (first usage)
  77. Web site: New Drug Application (NDA) 021446 . U.S. Food and Drug Administration (FDA) . Drugs@FDA . 21 November 2019 . 20 October 2020 . https://web.archive.org/web/20201020014353/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021446 . live .
  78. http://www.emea.europa.eu/humandocs/Humans/EPAR/lyrica/lyrica.htm EPAR: Lyrica
  79. Web site: New Drug Application (NDA) 009170 . U.S. Food and Drug Administration (FDA) . Drugs@FDA . 21 November 2019 . 24 October 2020 . https://web.archive.org/web/20201024040212/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=009170 . live .
  80. Web site: New Drug Application (NDA) 021911 . U.S. Food and Drug Administration (FDA) . Drugs@FDA . 21 November 2019 . 19 October 2020 . https://web.archive.org/web/20201019205652/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021911 . live .
  81. Web site: Drug Approval Package: Banzel (Rufinamide) NDA #021911 . U.S. Food and Drug Administration (FDA) . 30 May 2012 . https://web.archive.org/web/20191122035150/https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021911s000_TOC.cfm . 22 November 2019 . live . 21 November 2019.
  82. Web site: New Drug Application (NDA) 206709 . U.S. Food and Drug Administration (FDA) . Drugs@FDA . 21 November 2019 . 26 July 2020 . https://web.archive.org/web/20200726052816/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206709 . live .
  83. Web site: Drug Approval Package: Diacomit (stiripentol) . U.S. Food and Drug Administration (FDA) . 7 September 2018 . https://web.archive.org/web/20191122034549/https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/206709Orig1s000,207223Orig1s000TOC.cfm . 22 November 2019 . live . 21 November 2019.
  84. Web site: New Drug Application (NDA) 020646 . U.S. Food and Drug Administration (FDA) . Drugs@FDA . 21 November 2019 . 16 December 2020 . https://web.archive.org/web/20201216113439/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020646 . live .
  85. Web site: NDA: 020646. DrugPatentWatch. 19 May 2013. 23 March 2021. https://web.archive.org/web/20210323210249/https://www.drugpatentwatch.com/p/NDA/020646. live.
  86. Web site: New Drug Application (NDA) 020505 . U.S. Food and Drug Administration (FDA) . Drugs@FDA . 21 November 2019 . 19 October 2020 . https://web.archive.org/web/20201019065027/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020505 . live .
  87. Web site: New Drug Application (NDA) 005856 . U.S. Food and Drug Administration (FDA) . Drugs@FDA . 21 November 2019 . 19 October 2020 . https://web.archive.org/web/20201019034259/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=005856 . live .
  88. Web site: New Drug Application (NDA) 018081 . U.S. Food and Drug Administration (FDA) . Drugs@FDA . 21 November 2019 . 19 October 2020 . https://web.archive.org/web/20201019082528/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018081 . live .
  89. Web site: New Drug Application (NDA) 020427 . U.S. Food and Drug Administration (FDA) . Drugs@FDA . 21 November 2019 . 20 October 2020 . https://web.archive.org/web/20201020072637/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020427 . live .
  90. Web site: New Drug Application (NDA) 020789 . U.S. Food and Drug Administration (FDA) . Drugs@FDA . 21 November 2019 . 19 October 2020 . https://web.archive.org/web/20201019044822/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020789 . live .
  91. http://www.emea.europa.eu/humandocs/Humans/EPAR/zonegran/zonegran.htm EPAR: Zonegran.
  92. Bromley . Rebecca . Adab . Naghme . Bluett-Duncan . Matt . Clayton-Smith . Jill . Christensen . Jakob . Edwards . Katherine . Greenhalgh . Janette . Hill . Ruaraidh A. . Jackson . Cerian F. . Khanom . Sonia . McGinty . Ronan N. . Tudur Smith . Catrin . Pulman . Jennifer . Marson . Anthony G. . 2023-08-29 . Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child . The Cochrane Database of Systematic Reviews . 2023 . 8 . CD010224 . 10.1002/14651858.CD010224.pub3 . 1469-493X . 10463554 . 37647086.
  93. etal . Harden CL, Pennell PB, Koppel BS . May 2009 . Management issues for women with epilepsy—focus on pregnancy (an evidence-based review): III. Vitamin K, folic acid, blood levels, and breast-feeding: Report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the American Epilepsy Society . Epilepsia . 50 . 5 . 1247–55 . 10.1111/j.1528-1167.2009.02130.x . 19507305 . 221731995 . free.
  94. George . Ilena C. . 2017 . Practice Current: How do you treat epilepsy in pregnancy? . Neurology: Clinical Practice . 7 . 4 . 363–371 . 10.1212/cpj.0000000000000387 . 2163-0402 . 5648199 . 29185530.
  95. Bromley. Rebecca. Weston. Jennifer. Adab. Naghme. Greenhalgh. Janette. Sanniti. Anna. McKay. Andrew J. Tudur Smith. Catrin. Marson. Anthony G. Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child. 2014. 10.1002/14651858.CD010236.pub2. 25354543. Reviews. 2020. 10. CD010236. 7390020.
  96. Tomson . Torbjörn . Marson . Anthony . Boon . Paul . Canevini . Maria Paola . Covanis . Athanasios . Gaily . Eija . Kälviäinen . Reetta . Trinka . Eugen . July 2015 . Valproate in the treatment of epilepsy in girls and women of childbearing potential . Epilepsia . en . 56 . 7 . 1006–1019 . 10.1111/epi.13021 . 0013-9580 . free . 25851171 . 1 March 2024 . 1 March 2024 . https://web.archive.org/web/20240301162525/https://biblio.ugent.be/publication/6985189/file/7011646 . live .
  97. Birnbaum . Angela K. . Meador . Kimford J. . Karanam . Ashwin . Brown . Carrie . May . Ryan C. . Gerard . Elizabeth E. . Gedzelman . Evan R. . Penovich . Patricia E. . Kalayjian . Laura A. . Cavitt . Jennifer . Pack . Alison M. . Miller . John W. . Stowe . Zachary N. . Pennell . Page B. . for the MONEAD Investigator Group . 2020-04-01 . Antiepileptic Drug Exposure in Infants of Breastfeeding Mothers With Epilepsy . JAMA Neurology . 77 . 4 . 441–450 . 10.1001/jamaneurol.2019.4443 . 2168-6149. free . 31886825 . 6990802 .
  98. Web site: Norwegian Mother, Father and Child Cohort Study (MoBa) . 2023-10-11 . Norwegian Institute of Public Health . en . 12 October 2023 . https://web.archive.org/web/20231012044149/https://www.fhi.no/en/ch/studies/moba/ . live .
  99. Tomson . Torbjörn . Battino . Dina . Perucca . Emilio . April 2019 . Teratogenicity of antiepileptic drugs . Current Opinion in Neurology . 32 . 2 . 246–252 . 10.1097/WCO.0000000000000659 . 1473-6551 . 30664067 . 58608931 . 31 December 2023 . 22 November 2023 . https://web.archive.org/web/20231122193507/https://cdm21054.contentdm.oclc.org/digital/api/collection/IR/id/2527/download . live .
  100. Pennell . Page B. . Karanam . Ashwin . Meador . Kimford J. . Gerard . Elizabeth . Kalayjian . Laura . Penovich . Patricia . Matthews . Abigail . McElrath . Thomas M. . Birnbaum . Angela K. . MONEAD Study Group . 2022-04-01 . Antiseizure Medication Concentrations During Pregnancy: Results From the Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs (MONEAD) Study . JAMA Neurology . 79 . 4 . 370–379 . 10.1001/jamaneurol.2021.5487 . 35157004 . 2168-6149. 8845026 .
  101. Jazayeri . Dana . Graham . Janet . Hitchcock . Alison . O'Brien . Terence J. . Vajda . Frank J.E. . 2018 . Outcomes of pregnancies in women taking antiepileptic drugs for non-epilepsy indications . Seizure . 56 . 111–114 . 10.1016/j.seizure.2018.02.009 . 1059-1311 . 29471258 . free.
  102. Bittigau P, Sifringer M, Genz K . Antiepileptic drugs and apoptotic neurodegenereation in the developing brain. Proceedings of the National Academy of Sciences of the United States of America . 99 . 23 . 15089–94 . May 2002 . 12417760 . 10.1073/pnas.222550499. 137548. 2002PNAS...9915089B. etal. free.
  103. Manthey D, Asimiadou S . Sulthiame but not levetiracetam exerts neurotoxic effect in the developing rat brain. Exp Neurol. 193 . 2 . 497–503 . Jun 2005 . 15869952 . 10.1016/j.expneurol.2005.01.006. 1493015. etal.
  104. Katz I, Kim J . Effects of lamotrigine alone and in combination with MK-801, phenobarbital, or phenytoin on cell death in the neonatal rat brain. J Pharmacol Exp Ther . 322 . 2 . 494–500. Aug 2007 . 17483293 . 10.1124/jpet.107.123133. 12741109. etal.
  105. Kim J, Kondratyev A, Gale K . Antiepileptic drug-induced neuronal cell death in the immature brain: effects of carbamazepine, topiramate, and levetiracetam as monotherapy versus polytherapy. J Pharmacol Exp Ther . 323 . 1 . 165–73. Oct 2007 . 17636003 . 10.1124/jpet.107.126250. 2789311.
  106. Forcelli PA, Kim J, etal . Pattern of antiepileptic drug-induced cell death in limbic regions of the neonatal rat brain. Epilepsia . 52 . 12 . e207–11 . Dec 2011 . 22050285 . 10.1111/j.1528-1167.2011.03297.x . 3230752 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Anticonvulsant".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.